Investigational drug · Phase 3
TG103
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Type 2 Diabetes Mellitus, Overweight or Obesity.
Phase 3Last checked: Nov 19, 2026Latest source record: Apr 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
0 still active
All registered trials
11
Any phase or sponsor naming "TG103"
First trial start
2023
Nov 22, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TG103", any sponsor or status.
Conditions studied
As listed on its trial records.
- Type 2 Diabetes Mellitus
- Overweight or Obesity
Approved drugs for the same conditions: Type 2 diabetes · Obesity and weight management · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "TG103" as an intervention, largest first.
- A Study of TG103 Injection in Non-diabetic Overweight or ObesityPivotal-lookingCompleted
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.Industry
NCT05997576 · 675 participants · Start Nov 22, 2023 · Primary completion Feb 17, 2025
Drug: TG103 22.5 mg; Placebo · For: Overweight or Obesity
Sites: Shijiazhuang, China
- A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes MellitusPivotal-lookingCompleted
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.Industry
NCT06235086 · 632 participants · Start Apr 8, 2024 · Primary completion Feb 3, 2026
Drug: TG103; Dulaglutide · For: Type 2 Diabetes Mellitus
Sites: Beijing, China
- A Study of TG103 Injection Monotherapy in Treatment of Type 2 Diabetes MellitusPivotal-lookingCompleted
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.Industry
NCT06258148 · 465 participants · Start Apr 15, 2024 · Primary completion Jan 23, 2026
Drug: TG103; Placebo · For: Type 2 Diabetes Mellitus
Sites: Beijing, China
- A Study of TG103 Injection in the Management of Non-diabetic Overweight or ObesityPivotal-lookingCompleted
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.Industry
NCT06226090 · 314 participants · Start Feb 21, 2024 · Primary completion Sep 26, 2024
Drug: TG103 7.5 mg; Placebo 7.5 mg and 4 more · For: Obesity; Overweight
Sites: Shijiazhuang, China
- A Study of TG103 Injection in Type 2 Diabetes SubjectsPivotal-lookingStatus unknown
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.Industry
NCT05348122 · 240 participants (planned) · Start Jun 15, 2022 · Primary completion Nov 1, 2023
Drug: TG103,Q2W; TG103,QW and 3 more · For: Type 2 Diabetes Mellitus
Sites: Shijiazhuang, China
- A Study of TG103 Injection in Overweight/Obese Subjects With Type 2 DiabetesPivotal-lookingStatus unknown
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.Industry
NCT05063253 · 208 participants (planned) · Start Oct 2021 · Primary completion Mar 2024
Drug: TG103; Placebo · For: Type 2 Diabetes Mellitus
- A Study of TG103 Injection in Overweight or ObesityPivotal-lookingStatus unknown
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.Industry
NCT05299697 · 195 participants (planned) · Start May 20, 2022 · Primary completion Jun 30, 2023
Drug: TG103 15 mg; TG103 22.5 mg and 1 more · For: Overweight or Obesity
Sites: Baotou, China
- A Study of TG103 in Subjects With Type 2 DiabetesStatus unknown
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
NCT04790006 · 54 participants (planned) · Start Apr 2021 · Primary completion Mar 2022
Drug: TG103; Placebo · For: Type 2 Diabetes
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.Industry
NCT04855292 · 48 participants · Start Jul 1, 2021 · Primary completion Dec 1, 2022
Drug: TG103 injection; Placebo · For: Diabetes
Sites: Beijingcun, China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
NCT03990090 · 32 participants · Start Jul 29, 2019 · Primary completion Nov 11, 2020
Drug: TG103; Placebo · For: Healthy
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare.
Bhat S, Fernandez CJ, Lakshmi V, et al. · World J Cardiol 2025
- Emerging pharmacotherapies for obesity: A systematic review.
Kokkorakis M, Chakhtoura M, Rhayem C, et al. · Pharmacol Rev 2025
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of TG103 injection in participants who are overweight or obese: a randomized, double-blind, placebo-controlled, multiple-dose phase 1b study.
Lin D, Xiao H, Yang K, et al. · BMC Med 2024
- Safety, pharmacokinetics, and pharmacodynamics of TG103, a novel long-acting GLP-1/Fc fusion protein after a single ascending dose in Chinese healthy subjects.
Jin J, Cui G, Mi N, et al. · Eur J Pharm Sci 2023
Also in development for Type 2 Diabetes Mellitus
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- ElecoglipronPhase 39 trials
AstraZeneca · Type 2 Diabetes Mellitus, Obesity, Overweight
- LenbelintideAZD6234Phase 39 trials
AstraZeneca · Obesity or Overweight, Obesity, Overweight
- ASC30 A1ASC30Phase 35 trials
Ascletis Pharma (China) Co., Limited · Chronic Weight Management, Obesity, Overweight
- SHR-3167Phase 35 trials
Jiangsu HengRui Medicine Co., Ltd. · Diabetes Mellitus, Type 2, Type 2 Diabetes, Type 2 Diabetes Mellitus
- HTD1801Berberine UrsodeoxycholatePhase 34 trials
Shenzhen HighTide Biopharmaceutical Ltd. · T2DM (Type 2 Diabetes Mellitus), Nonalcoholic Steatohepatitis (NASH), Type 2 Diabetes
- DA-302168SPhase 33 trials
Chendu DIAO Pharmaceutical Group CO., LTD. · Overweight and Obesity, Type 2 Diabetes Mellitus
- Exendin-4 Fc fusion proteinJY09Phase 32 trials
Beijing Dongfang Biotech Co., Ltd. · Type2 Diabetes Mellitus, Type 2 Diabetes Mellitus
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.